In:
Oncology, S. Karger AG, Vol. 93, No. 2 ( 2017), p. 92-98
Abstract:
〈 b 〉 〈 i 〉 Objectives: 〈 /i 〉 〈 /b 〉 There is little information on the risk factors for hepatocellular carcinoma (HCC) and outcome of treatment with an all-oral combination of direct-acting antiviral regimens following eradication of hepatitis C virus (HCV) RNA. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The study subjects were 1,170 patients with HCV genotype 1-related chronic liver disease treated with either NS5A inhibitor plus NS3/4A protease inhibitor ( 〈 i 〉 n 〈 /i 〉 = 707), NS5A inhibitor plus NS5B polymerase inhibitor ( 〈 i 〉 n 〈 /i 〉 = 345), or NS5A inhibitor, NS3/4A protease inhibitor plus ritonavir ( 〈 i 〉 n 〈 /i 〉 = 118), for 12-24 weeks. All patients were free of HCC before and during therapy. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 In this retrospective study, 22 patients developed HCC during the follow-up (time from the end of antiviral therapy until the last visit: 1.3 years). At 1 and 2 years after completion of the treatment, the cumulative HCC rates for the whole group were 1.8 and 2.3%, respectively, and 1.4 and 1.8%, respectively, for 1,065 patients who showed sustained virological response (SVR). The risk factors for HCC identified by multivariate analysis were hypoalbuminemia, thrombocytopenia, a high α-fetoprotein level, and non-SVR for all patients, and hypoalbuminemia and a high α-fetoprotein level for patients with SVR. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Eradication of HCV RNA by direct-acting antiviral regimens might reduce the risk of HCC. Albumin and α-fetoprotein levels are significant risk factors for HCC.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2017
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink
